MedPath

Comparative Mixture of Non-racemic and Racemic Enantiomers of Bupivacaine in Cesarean

Phase 3
Withdrawn
Conditions
Cesarean Delivery
Interventions
Registration Number
NCT01303107
Lead Sponsor
Cristália Produtos Químicos Farmacêuticos Ltda.
Brief Summary

The purpose of this study is to determine if the mixture of enantiomers of bupivacaine (bupivacaine S75:R25) dos not represent inferiority efficacy and safety compare to the racemic mixture of enantiomers of bupivacaine (bupivacaine S50:R50).

Detailed Description

The enantiomeric mixture of bupivacaine S75:R25 (75% levobupivacaine and 25% bupivacaine) was develop to be a safety regional anesthetic in substitution to racemic bupivacaine (S50:R50).

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  • parturients at term
  • ASA (American Society of Anesthesiologists) I or ASA II
  • elective cesarean section with low risk labor
  • pre-natal follow-up
  • patient consent
Exclusion Criteria
  • relative or absolute contraindications for spinal anesthesia
  • history of hypersensitivity to the local anesthetics
  • use of opioids during labor
  • labor lasting more than 12 hours or less than 1 hour
  • complications of pregnancy such as placenta previa, pre-eclampsia or eclampsia; maternal-fetal malnutrition;important accidents during pregnancy.
  • spinal lesions, peripheral neuropathies or any other neurologic disorders that lead to changes of sensitivity and/or motricity
  • decompensated diabetes or hypertension
  • history of alcohol and/or drug abuse
  • cardiopathies, especially myocardiopathies and valvulopathies; important cognitive changes
  • changes in safety exams
  • twin pregnancy;
  • signs of intrauterine distress, and abnormalities of fetal vitality, prematurity

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
bupivacaine S50:R50Bupivacaine3 ml subarachnoid block
bupivacaine S75:R25Bupivacaine3 ml for subarachnoid block
Primary Outcome Measures
NameTimeMethod
latency of sensitive block at T6loss of pain in T6

The anesthesiologist will evaluate the loss of pain to pin-prick in T10.

Secondary Outcome Measures
NameTimeMethod
duration of the anesthesiarecovery of the sensibility

Time to recover the sensibility due to the anesthetic

Degree of motor blockEnd of motor block

Evaluated by the Bromage scale after the injection of the anesthetic solution

maximal level of the sensitive blockadelast level of sensitive blockade

Evaluation by pin-prick every 2 minutes after the injection of the anesthetic solution.

Maternal cardiocirculatory and respiratory parametersDuring the study

systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), and oxygen saturation (SpO2) are evaluate during the study

Parturients ambulationregression of the motor blockade

Will be measured the time that the parturients ambulate, due to de regression of the motor blockade

Visceral painsuture of the peritoneum

Visceral pain will be assessed at the time of suture of the peritoneum.

Neonatal repercussionsbirth of the neonatal

Evaluation of the Apgar index in the first and fifth minutes.

Trial Locations

Locations (2)

Irmandade da Santa Casa da Misericórdia de Santos

🇧🇷

Santos, São Paulo, Brazil

Irmandade da Santa Casa de Misericóridia de São Paulo

🇧🇷

São Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath